KARABELAS ARGERIS N 4
4 · REGENXBIO Inc. · Filed Jul 3, 2024
Insider Transaction Report
Form 4
REGENXBIO Inc.RGNX
KARABELAS ARGERIS N
Director
Transactions
- Sale
Common Stock
2024-07-01$11.27/sh−10,000$112,691→ 11,286 total - Exercise/Conversion
Common Stock
2024-07-01$3.76/sh+10,000$37,600→ 21,286 total - Exercise/Conversion
Stock Options (Right to Buy)
2024-07-01−10,000→ 30,000 totalExercise: $3.76Exp: 2025-05-18→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $10.98 to $11.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter.